Filed: 2/12/2026ACC: 0002006045-26-000002
📋 What this filing means
SYMBIOSIS CAPITAL PARTNERS, LLC filed this quarterly 13F‑HR report disclosing 11 equity positions with a total reported market value of $109.50M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
11
Positions
$109.50M
Total AUM (reported)
21.05M
Total Shares
Allocation by class
COM NEW$36.97M33.8%
COM SHS$21.93M20.0%
COM CL A$19.70M18.0%
COM$18.80M17.2%
ADS$12.09M11.0%
*W EXP 08/01/203$3.0K0.0%
Portfolio Concentration
Top 3$50.60M46.2%
4–10$58.89M53.8%
11–25$3.0K0.0%
Top 3 weight
46.2%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 21.05M
Sole
Full voting authority
21.05M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole11
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings11
Rows:
Evommune, Inc.
SOLEShares1.28M
TypeSH
Market value$21.93M
20.03%
Sole
1.28M
Shared
0.00
None
0.00
Verastem Inc
SOLEShares2M
TypeSH
Market value$15.44M
14.10%
Sole
2M
Shared
0.00
None
0.00
Aldeyra Therapeutics Inc
SOLEShares2.56M
TypeSH
Market value$13.23M
12.09%
Sole
2.56M
Shared
0.00
None
0.00
Precigen Inc
SOLEShares3M
TypeSH
Market value$12.54M
11.45%
Sole
3M
Shared
0.00
None
0.00
Inventiva S.A.
SOLEShares2.60M
TypeSH
Market value$12.09M
11.04%
Sole
2.60M
Shared
0.00
None
0.00
Nuvation Bio Inc
SOLEShares1.25M
TypeSH
Market value$11.20M
10.23%
Sole
1.25M
Shared
0.00
None
0.00
Rani Therapeutics Holdings, Inc.
SOLEShares6.30M
TypeSH
Market value$8.51M
7.77%
Sole
6.30M
Shared
0.00
None
0.00
Aardvark Therapeutics, Inc.
SOLEShares476.60K
TypeSH
Market value$6.26M
5.71%
Sole
476.60K
Shared
0.00
None
0.00
Clene Nanomedicine Inc.
SOLEShares770.50K
TypeSH
Market value$4.52M
4.13%
Sole
770.50K
Shared
0.00
None
0.00
Generation Bio Co
SOLEShares665K
TypeSH
Market value$3.78M
3.45%
Sole
665K
Shared
0.00
None
0.00
Surrozen, Inc.
SOLEShares150K
TypeSH
Market value$3.0K
<0.01%
Sole
150K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Evommune, Inc.SOLE | COM SHS | 1.28M | SH | $21.93M 20.03% | 1.28M | 0.00 | 0.00 |
Verastem IncSOLE | COM NEW | 2M | SH | $15.44M 14.10% | 2M | 0.00 | 0.00 |
Aldeyra Therapeutics IncSOLE | COM NEW | 2.56M | SH | $13.23M 12.09% | 2.56M | 0.00 | 0.00 |
Precigen IncSOLE | COM | 3M | SH | $12.54M 11.45% | 3M | 0.00 | 0.00 |
Inventiva S.A.SOLE | ADS | 2.60M | SH | $12.09M 11.04% | 2.60M | 0.00 | 0.00 |
Nuvation Bio IncSOLE | COM CL A | 1.25M | SH | $11.20M 10.23% | 1.25M | 0.00 | 0.00 |
Rani Therapeutics Holdings, Inc.SOLE | COM CL A | 6.30M | SH | $8.51M 7.77% | 6.30M | 0.00 | 0.00 |
Aardvark Therapeutics, Inc.SOLE | COM | 476.60K | SH | $6.26M 5.71% | 476.60K | 0.00 | 0.00 |
Clene Nanomedicine Inc.SOLE | COM NEW | 770.50K | SH | $4.52M 4.13% | 770.50K | 0.00 | 0.00 |
Generation Bio CoSOLE | COM NEW | 665K | SH | $3.78M 3.45% | 665K | 0.00 | 0.00 |
Surrozen, Inc.SOLE | *W EXP 08/01/203 | 150K | SH | $3.0K <0.01% | 150K | 0.00 | 0.00 |